Variants of human papillomavirus types 53, 58 and 66 identified in Central Brazil

被引:13
作者
Daniela Marreco Cerqueira
Geni Noceti de Lima Camara
Márcio Rojas da Cruz
Evandro Oliveira Silva
Marcelo de Macedo BrÍgido
Luciano Gonçalves de Souza Carvalho
Cláudia Renata Fernandes Martins
机构
[1] Departamento de Biologia Celular, Instituto de Biologia, Universidade de Brasília, Brasilia
[2] Agencia Nac. de Vigilancia Sanit., Ministry of Health, Brasília
[3] Secretaria de Saude do Distrito Fed., Brasília
[4] Departamento de Biologia Celular, Instituto de Biologia, Camp. da Univ. de Brasília
关键词
Cervical neoplasia; Genotyping; Human papillomavirus; L1; gene; Variants;
D O I
10.1023/A:1022386323921
中图分类号
学科分类号
摘要
The present study on molecular characterization of human papillomaviruses occurring in Central Brazil, describes two variants each of HPV-53 and HPV-58 and one variant of HPV-66 detected in samples from smears of women showing cervical intraepithelial neoplasia grade II (CIN II). Samples were assayed by PCR using MY09/MY 11 consensus primers, followed by restriction fragment length polymorphism typing. The five isolates showed atypical restriction fragment length profile and MY09/MY11 L1 PCR products were subsequently sequenced. Isolate Bsb-02 and Bsb-08 showed, respectively, 99% similarity to HPV-58 IS404 and 100% to HPV-58 IS417 previously described in the African Continent. Isolates Bsb-61 and Bsb-63 showed 98% similarity to HPV-53, and isolate Bsb-68, 97% similarity to HPV-66. Amino acid substitutions were found in two samples: one in Bsb-02 (T to N) at position 375 and the other in Bsb-61 (S to C) at position 343. Although all the substitutions in Bsb-68 proved to be silent, this sample showed the highest value of pairwise evolutionary distance (2.05%). In countries such as Brazil, where the virus prevalence is high and ethnicity, as well as socio-demographic characteristics, vary according to different regions, HPV variability must be wider and not yet clearly defined.
引用
收藏
页码:83 / 87
页数:4
相关论文
共 20 条
[1]  
Bosch F.X., Manos M.M., Munoz N., Sherman M., Jansen A.M., Peto J., Schiffman M.H., Moreno V., Kurman R., Shah K.V., J Natl Cancer Inst, 87, pp. 796-802, (1994)
[2]  
Van Ranst M., Kaplan J.B., Burk R.D., J Gen Virol, 73, pp. 2653-2660, (1992)
[3]  
Chow L.T., Broker T.R., Small DNA Tumor Viruses, pp. 267-301, (1997)
[4]  
Rolon P.A., Smith J.S., Munoz N., Klug S.J., Bosch X., Llamosas F., Meijer C.J.L.M., Walboomers J.M.M., Int J Cancer, 85, pp. 486-491, (2000)
[5]  
Doorbar J., Sterling J.C., The Biology of Human Papillomaviruses, pp. 10-23, (2001)
[6]  
Cancer Epidemiology Database, (2001)
[7]  
Cerqueira D., Camara G., Cruz M., Neves D., Silva E., Carvalho L., Medeiros R., Martins C., 19th International Papillomavirus Conference, (2001)
[8]  
Camara G., Cerqueira D., Oliveira A., Bonfim P., Carvalho L., Martins C., 20th International Papillomavirus Conference, (2002)
[9]  
Camara G.N.N.L., Cerqueira D.M., Neves D., Silva E.O., Carvalho L.G.S., Martins C.R.F., Rev Saúde DF, 12, 3, (2001)
[10]  
Bernard H.-U., Chan S.-Y., Manos M.M., Ong C.-K., Villa L.L., Delius H., Peyton C.L., Bauer H.M., Wheeler C.M., J Infect Dis, 170, pp. 1077-1085, (1994)